Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 14/20 | 0.77 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.71 |
| ▸ | INSR | P06213 | 3/20 | 0.66 |
| ▸ | IGF1R | P08069 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20214436 | 1.00 | MAP4K1 (0.77) | MAP4K1ALKINSRIGF1R | |
| SCHEMBL29805906 | 1.00 | MAP4K1 (0.77) | MAP4K1ALKINSRIGF1R | |
| SCHEMBL24040087 | 0.90 | MAP4K1 (0.85) | MAP4K1ALKINSRIGF1R | |
| SCHEMBL24040051 | 0.90 | MAP4K1 (0.85) | MAP4K1ALKINSRIGF1R | |
| SCHEMBL30183975 | 0.90 | MAP4K1 (0.62) | MAP4K1ALKINSRIGF1R | |
| SCHEMBL25337779 | 0.90 | MAP4K1 (0.62) | MAP4K1ALKINSRIGF1R | |
| SCHEMBL25338542 | 0.89 | MAP4K1 (0.61) | MAP4K1ALKINSR | |
| SCHEMBL20214585 | 0.87 | MAP4K1 (1.00) | MAP4K1ALKINSRIGF1R | |
| SCHEMBL30184145 | 0.87 | ALK (0.62) | MAP4K1ALKINSR | |
| SCHEMBL24039925 | 0.86 | MAP4K1 (0.72) | MAP4K1ALKINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114829344-A | Novel pyrimidine derivative and use thereof | 韩国化学研究院 | 2022-07-29 | — | — | CN | claimed |
| EP-3548479-A1 | ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS | ARIAD Pharmaceuticals, Inc. (US) | 2019-10-09 | — | — | EP | claimed |
| WO-2018102366-A1 | ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | WO | claimed |
| CN-118976029-A | Pharmaceutical composition for preventing or treating parkinson's disease or nonalcoholic steatohepatitis | 韩国化学研究院 | 2024-11-19 | — | — | CN | disclosed |
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-15 | — | — | US | disclosed |
| CN-114829344-B | Pyrimidine derivatives and pharmaceutical compositions containing the same | 韩国化学研究院 | 2024-08-13 | — | — | CN | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| EP-4079726-A1 | NOVEL PYRIMIDIN DERIVATIVE AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2022-10-26 | — | — | EP | disclosed |
| CN-114829344-A | Novel pyrimidine derivative and use thereof | 韩国化学研究院 | 2022-07-29 | — | — | CN | disclosed |
| US-11180482-B2 | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| WO-2021125803-A1 | NOVEL PYRIMIDIN DERIVATIVE AND USE THEREOF | 한국화학연구원 | 2021-06-24 | — | — | WO | disclosed |
| EP-3548479-A1 | ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS | ARIAD Pharmaceuticals, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018102366-A1 | ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | MAP4K1 244/4885ALK 2070/4885INSR 1636/4885 |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | MAP4K1 244/4885ALK 2070/4885INSR 1636/4885 |
| US-11180482-B2 | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors | STK16, STK4, STK26 | MAP4K1 26/4885ALK 887/4885INSR 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.